The DOI matches its Crossref record.
Mortality in acromegaly: a 20-year follow-up study
Open accessAbstract
Objective: It is unclear whether mortality still is increased in acromegaly and whether there are gender-related differences. We dynamically assessed outcome during long-term follow-up in our nationwide cohort. Patients and methods: We studied standardized mortality ratios (SMRs) relative to the general population and causes of death in acromegaly ( n =333) compared with age- and gender-matched controls ( n =4995). Results: During 20 (0–33) years follow-up, 113 (34%) patients ( n =333, 52% women) and 1334 (27%) controls ( n =4995) died ( P =0.004). SMR (1.9, 95% CI: 1.53–2.34, P <0.001) and all-cause mortality (OR 1.6, 95% CI: 1.2–2.2, P <0.001) were increased in acromegaly. Overall distribution of causes of death ( P <0.001) differed between patients and controls but not cardiovascular (34% vs 33%) or cancer deaths (27% vs 27%). In acromegaly, but not in controls, causes of deaths shifted from 44% cardiovascular and 28% cancer deaths during the first decade, to 23% cardiovascular and 35% cancer deaths during the next two decades. In acromegaly, cancer deaths were mostly attributed to pancreatic adenocarcinoma ( n =5), breast ( n =4), lung ( n =3) and colon ( n =3) carcinoma. In acromegaly, men were younger than women at diagnosis (median 44.5 vs 50 years, P <0.001) and death (67 vs 76 years, P =0.0015). Compared with controls, women (36% vs 25%, P <0.01), but not men (31% vs 28%, P =0.44), had increased mortality. Conclusions: In acromegaly, men are younger at diagnosis and death than women. Compared with controls, mortality is increased during 20 years of follow-up, especially in women. Causes of deaths shift from predominantly cardiovascular to cancer deaths.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Pituitary-Tumor Endocrinopathies
Melmed, S. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1810772 · Cited by 604
A Consensus Statement on acromegaly therapeutic outcomes
Melmed, S., Bronstein, M. D., Chanson, P., Klibanski, A., Casanueva, F. F., Wass, J. A. H., Strasburger, C. J., Luger, A., Clemmons, D. R., & Giustina, A. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0058-5 · Cited by 561
A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update
Giustina, A., Barkan, A., Beckers, A., Biermasz, N., Biller, B. M. K., Boguszewski, C., Bolanowski, M., Bonert, V., Bronstein, M. D., Casanueva, F. F., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz096 · Cited by 371
Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update
Gadelha, M. R., Kasuki, L., Lim, D. S. T., & Fleseriu, M. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00115 · Cited by 363
Clinical Biology of the Pituitary Adenoma
Melmed, S., Kaiser, U. B., Lopes, M. B., Bertherat, J., Syro, L. V., Raverot, G., Reincke, M., Johannsson, G., Beckers, A., Fleseriu, M., et al. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac010 · Cited by 321
Acromegaly: pathogenesis, diagnosis, and management
Fleseriu, M., Langlois, F., Lim, D. S. T., Varlamov, E. V., & Melmed, S. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00244-3 · Cited by 279
Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database
Petrossians, P., Daly, A. F., Natchev, E., Maione, L., Blijdorp, K., Sahnoun-Fathallah, M., Auriemma, R., Diallo, A. M., Hulting, A.-L., Ferone, D., et al. (2017) · Endocrine-Related Cancer · doi:10.1530/erc-17-0253 · Cited by 263
Gorenek, B., Boriani, G., Dan, G.-A., Fauchier, L., Fenelon, G., Huang, H., Kudaiberdieva, G., Lip, G. Y. H., Mahajan, R., Potpara, T., et al. (2018) · EP Europace · doi:10.1093/europace/euy051 · Cited by 43
Metadata
- Authors
- Ritvonen, E., Löyttyniemi, E., Jaatinen, P., Ebeling, T., Moilanen, L., Nuutila, P., Kauppinen-Mäkelin, R., & Schalin-Jäntti, C.
- Venue
- Endocrine-Related Cancer
- Publisher
- Bioscientifica
- Published
- 2016-06
- Volume
- 23
- Issue
- 6
- Pages
- 469-480
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- OpenAlex
- W2463950503
- Cited by
- 173
- References
- 0
- FWCI
- 13.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.